RXRX — Recursion Pharmaceuticals, Inc. - Class A Common Stock
Session close: $2.83. Regular-session share volume: 37,421,816. Change from previous close: +3.86%.
Key developments
Morgan Stanley maintained a Hold rating on Recursion while lowering its price target, reflecting a tempered assessment of the company's market position and outlook. Separate commentary noted the stock has been weak over the past year and questioned the original thesis around clinical risk, cash needs and partnership dependence.
Company news Morgan Stanley Maintains Hold Rating on Recursion Pharmaceuticals, Lowers Price Target · Company news What Recursion Pharmaceuticals Investors Missed Before The Fall
News sources
Company news Morgan Stanley Maintains Hold Rating on Recursion Pharmaceuticals, Lowers Price Target · Company news What Recursion Pharmaceuticals Investors Missed Before The Fall